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MaThe current system for postmarket surveillance of medical devices in the United States is limited. To help change this
paradigm for transcatheter valve therapies (TVTs), starting with transcatheter aortic valve replacement, the Society
of Thoracic Surgeons and the American College of Cardiology partnered to form the TVT Registry program in close
collaboration with the U.S. Food and Drug Administration and the Center for Medicare and Medicaid Services. The goal of
the TVT Registry is to measure and improve quality of care and patient outcomes in clinical practice and to have a pivotal
role in the scientiﬁc evidence and surveillance for medical devices. Challenges were faced in the early experience of
the registry included developing multistakeholder partnerships, data collection requirements, and the use of the registry
for pre- and post-market device evaluations. In addressing these challenges, the TVT Registry demonstrates that it is
feasible for professional societies to assume a pivotal role in pre- and/or post-market studies, leveraging a clinical
registry infrastructure. Sharing the TVT Registry experience may help other professional societies and stakeholders better
anticipate and plan for these challenges. (J Am Coll Cardiol Intv 2015;8:377–81) © 2015 by the American College of
Cardiology Foundation.T o help address the limitations of medical de-vice surveillance in the United States and toassess quality of care and patient outcomes
in current clinical practice, the Society of Thoracic
Surgeons (STS) and American College of Cardiology
(ACC) partnered to form the Transcatheter Valve
Therapy (TVT) Registry (1). Initially focused on trans-
catheter aortic valve replacement (TAVR), the pro-
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378programs, yet was speciﬁcally designed to
enable the professional societies to work
with other stakeholders to enhance the
evaluation, approval, and post-market sur-
veillance of new device strategies in the
United States. As with any new program, a
number of challenges have been faced since
the TVT Registry’s inception.
The goal of this paper is to brieﬂy sum-
marize the early experience of the TVT
Registry, focusing on key issues including
multistakeholder partnerships, data collec-
tion requirements, and the role of the clinical
registry program with regard to both pre- and
post-market research and device surveil-
lance. It is hoped that the insights gained
from the early experience of the TVT registry
may help inform other professional societies
and stakeholders interested in developingsimilar programs. In addition, this paper serves as a
prelude to regular reports of TVT Registry data to be
published in the Journal of the American College of
Cardiology and JACC: Cardiovascular Interventions.TIMELINE AND SELECTED
ACCOMPLISHMENTS
The design, core functions, and overall goals of the
TVT Registry have been previously described (1). The
program has had a number of key events and ac-
complishments to date, which are summarized in
Table 1 (1,4–7). The TVT Registry plans to publish
regular reports summarizing key data and trends
from the program in future issues of the Journal of the
American College of Cardiology. As a prelude to these
regular data reports, this paper relates insights from
the early experience of the TVT Registry to help other
professional societies or organizations interested in
developing similar programs. The TVT Registry has
faced signiﬁcant challenges in attempting to have a
pivotal role in pre- and post-market device evalua-
tions and surveillance. The remainder of this paper is
therefore focused on key aspects of these challenges,
including multistakeholder partnerships, data re-
quirements and sustained participation, post-market
data and device surveillance, post-approval studies,
and Investigational Device Exemption (IDE) and pre-
market studies.MULTISTAKEHOLDER PARTNERSHIPS
One key action for the TVT Registry was the inclusion
of representatives from the FDA and CMS on theSteering Committee. Furthermore, it was quickly
realized that it is critical to work jointly with both pre-
and post-market personnel at the FDA to effectively
address the medical device life cycle. Moreover, the
TVT Registry has a Stakeholder Advisory Committee
with representation from industry, consumer and
patient organizations, hospitals and health systems,
professional societies, the National Institutes of
Health, the FDA, and the CMS. Although it is chal-
lenging to balance the perspectives and input from
various stakeholders, we believe that the commit-
ment to multistakeholder partnerships in the gover-
nance of the registry program is a critical component
for long-term success. Stakeholders must be able to
see that their input helps shape the strategic vision
and goals of the registry program, such as the execu-
tion of collaborative projects including post-approval
studies, device surveillance, publications with TVT
Registry data, and plans for public reporting. Figure 1
depicts the various stakeholders and primary pro-
grammatic output goals of the TVT Registry.
DATA REQUIREMENTS AND
SUSTAINED PARTICIPATION
The scope of data collection is a key challenge for the
TVT Registry. The initial dataset resulted from
collaboration between the professional societies, the
FDA, and the CMS, including harmonization with the
Valve Academic Research Consortium data elements.
The dataset needed to meet the requirements of
multiple stakeholders, including assessment of pa-
tient characteristics, procedure indications and re-
sults, complications, and longitudinal outcomes. The
desire to use the registry for pre- and post-market
studies was also considered.
It is difﬁcult to balance data collection sufﬁcient to
support the various goals of the TVT Registry stake-
holders yet not impose undue burden on sites. Mini-
mizing unnecessary or redundant data collection is a
top priority; the TVT Registry has initiated a dedi-
cated effort to reduce the data elements collected. In
the future, the increased availability of electronic
data (e.g., from electronic health records) may sup-
port data capture for programs like the TVT Registry
and further reduce, or in some cases obviate, the need
for data collection.
In addition, there must be sustained site partici-
pation to fulﬁll the goals of the TVT Registry as a
clinical quality program, device surveillance network,
and infrastructure for pre- and post-market studies.
The TVT Registry satisﬁes the requirements of the
CMS national coverage determination, which directly
supports site participation. Anticipating that the
TABLE 1 Timeline and Selected Events/Accomplishments for the TVT Registry
Year (Month Where
Applicable) Event/Accomplishment
2011 (July) TVT Registry proposed at the FDA Advisory Panel for Edwards Sapien
Valve.
2011
(July–September)
Development of standard data elements and deﬁnitions for the TVT
Registry in collaboration with the FDA and CMS and consistent with
the Valve Academic Research Consortium, STS, and NCDR program
data elements (1).
2011 (December) Launch of the TVT Registry (Version 1).
2011–2012 Professional society collaboration on the development of standards for
patient selection and procedural performance to help support
anticipated CMS National Coverage Determination, which was
released in May 2012.
2011 to present Data are submitted by trained data managers using a web application
with data quality checks, following the data quality programs
established by STS and NCDR (4). The data quality program for
the STS and NCDR registry programs include training of site data
managers, technical support for data submission (e.g., range checks
and data quality reporting), data analytics (e.g., missingness and
validity of data entries), and auditing.
2011 to present Relationship with the Duke Clinical Research Institute to serve as
an analytic center for the TVT Registry, including data analytics,
reporting, and event adjudication.
2011 to present Convening of 4 national committees: Steering, Research and
Publications, Stakeholder Advisory, and Data Monitoring. These
committees follow the established governance of the STS and NCDR
registry programs and were developed with input from the FDA, the
CMS, and 4 professional societies (STS, ACC, American Association
for Thoracic Surgery, and Society for Cardiovascular Angiography
and Interventions).
2012–2013 Development of PAS and IDE protocols.
2012–2014 Initial presentations and publication of data, including in-hospital
outcomes for the initial 7,710 patients in the United States (5).
Multiple abstracts were submitted to national meetings in the ﬁrst 2
years of the registry, including one selected for the Richard E. Clark
Award at the 2014 STS Annual Meeting, and another presented as a
late-breaking clinical trial at the 2014 ACC Scientiﬁc Sessions.
2012–2014 In the ﬁrst year of the TVT Registry (i.e., through 2012), 156 U.S.
centers joined, and 2,400 commercial TAVR records were entered in
the registry. As of June 2014, the TVT Registry has 319 participating
centers, and there are more than 18,500 TAVR cases in the registry.
2013 (August) Demonstration of rapid data analytics to help inform a policy
recommendation with regard to TAVR alternative access, at the
behest of the FDA (6).
2013 Initiation of working groups for TAVR risk models and a mitral
procedure module; ﬁrst TVT risk model (for in-hospital risk-adjusted
mortality) completed May 2014, for implementation in the hospital
quality benchmark reports.
2013 Joining the International Consortium of Cardiovascular Device
Registries to begin global harmonization of medical device
registries (7).
2014 Eleven research proposal applications approved for manuscript
development, funded by the TVT Registry.
2014 (June) TVT Registry version 2, including reduction of TAVR data elements and
modiﬁcation of some data elements on the basis of site feedback,
and addition of the mitral module of the TVT Registry.
ACC ¼ American College of Cardiology; CMS ¼ Centers for Medicare and Medicaid Services; FDA ¼ U.S. Food and
Drug Administration; IDE ¼ Investigational Device Exemption; NCDR ¼ National Cardiovascular Data Registry;
PAS ¼ post-approval study; STS ¼ Society of Thoracic Surgeons; TAVR ¼ transcatheter aortic valve replacement;
TVT ¼ transcatheter valve therapy.
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379coverage with evidence requirement may be removed
at some point, there will need to be adequate value
delivered for sites to continue participation. This may
include the value of quality of care measurement and
national benchmarking reports, meeting payer and/or
state quality reporting needs, the use of the registry
data for documenting performance improvement for
sites and clinicians, the desire for ongoing participa-
tion in device surveillance efforts in collaboration
with the FDA, and the ability for sites to participate in
pre- and/or post-market studies that are conducted
using the TVT Registry infrastructure.
POST-MARKET DATA AND
DEVICE SURVEILLANCE
Over the past decade, registry programs including
the NCDR have conducted individual studies on de-
vice safety, and the FDA has collaborated with in-
vestigators for post-market research studies. The TVT
Registry extends this competency by being designed
to serve as a device surveillance system to inform
regulators, clinicians, sponsors, and the public about
device performance. Although the vision of the reg-
istry as a device surveillance network is clear, a
number of challenges must be met. For example, the
system must be responsive to the needs and timelines
of regulatory and industry partners. Currently, the
TVT Registry, like most clinical registry programs,
receives data submitted by trained site personnel.
This process enhances data completeness and accu-
racy but does not constitute real-time surveillance.
The TVT Registry will need to enhance device sur-
veillance capabilities to optimally support the FDA’s
strategic plan for device surveillance (8).
POST-APPROVAL STUDIES
It is more challenging to operationalize clinical reg-
istries to conduct the formal post-approval studies
(PASs) that are mandated by the FDA as a condition of
device approval and have been traditionally executed
by industry. An explicit goal of the TVT Registry was
to use the registry infrastructure to conduct PASs.
The hope is to demonstrate efﬁciencies by using
existing registry program sites, contracts, and data
collection, augmented by any additional re-
quirements for a speciﬁc PAS. Moreover, the TVT
Registry data could serve as a de facto PAS by virtue
of the capture of virtually all patients receiving a
device. In the ﬁrst year of the TVT Registry, a PAS for
the Edwards Sapien valve was successfully designed
and approved. Whether clinical registry programs likeTVT may be used for a given PAS will be determined
by the FDA on a case-by-case basis. The burden is on
the TVT Registry to be designed to provide the data
that the FDA requires and to ensure that the beneﬁts
FIGURE 1 Transcatheter Valve Therapy Registry
Stakeholders and Primary Program Output Goals
ACC ¼ American College of Cardiology; ARO ¼ Academic
Research Organization; AATS ¼ American Association for
Thoracic Surgery; CMS ¼ Centers for Medicare and Medicaid
Services; DCRI ¼ Duke Clinical Research Institute; FDA ¼ Food
and Drug Administration; IDE ¼ Investigational Device Exemp-
tion; STS ¼ Society of Thoracic Surgeons; SCAI ¼ Society for
Cardiovascular Angiography and Interventions.
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structure are realized.
IDE AND PRE-MARKET STUDIES
Another goal of the TVT Registry is to evaluate all
use of devices in clinical practice, which may extend
beyond currently approved indications. The CMS
National Coverage Determination distinguishes
labeled from unlabeled uses and requires that unla-
beled uses be furnished under coverage with evi-
dence development as a condition of Medicare
coverage. The TVT Registry provides an opportunity
to evaluate the effectiveness of TAVR (and other
new technology in the future) in broader indications
under an IDE, in collaboration with the FDA and
industry. However, the complex regulatory re-
quirements involved in IDE studies are a signiﬁcant
challenge.
Although the FDA has the authority to waive
certain IDE requirements, waivers are granted under
rare circumstances, and this process requires legal
consultation and extensive documentation to justify
them.
An additional aspiration of the TVT Registry is to
support pre-market studies. The TVT Registry could
serve as a hospital network from which to recruit
sites, and existing TVT Registry data could be used to
inform trial planning (e.g., targeting sites that do a
certain volume of speciﬁc procedures). The routinelycollected data for the TVT Registry could serve as a
core dataset for a given clinical trial, with additional
data elements collected for a speciﬁc study as
needed. Ongoing TVT Registry data collection after
study completion could be used for post-trial sur-
veillance. It is also recognized that clinical trials may
involve both U.S. and international sites. Hence, with
support of the FDA, the TVT Registry has joined the
International Consortium of Cardiovascular Device
Registries (7). Goals of this collaboration is harmo-
nization of data elements and pursuit of collabora-
tive research. Therefore, it holds potential for the
use of the TVT Registry and collaborating interna-
tional programs with regard to the conduct of clin-
ical trials, although this potential has not been
realized to date.
In addition, the device industry has expressed
reasonable concerns about the ability of clinical reg-
istry programs to meet pre-market study re-
quirements for data integrity, monitoring, and
timeliness. However, the FDA is supportive of the
concept of potential efﬁciencies offered by clinical
registry programs like the TVT Registry. In sum, the
role of clinical registry programs for IDE and pre-
market studies is appealing in concept and will be
pursued, but remains uncertain.
CONCLUSIONS
Extending the capabilities of traditional clinical
registry programs, the TVT Registry was designed
with multistakeholder collaboration to support de-
vice safety and effectiveness monitoring in clinical
practice. An a priori goal was to try to bridge the
pre- to post-market device life cycle and be a
“living platform” for safety, efﬁcacy, and effective-
ness data that can accommodate new technologies/
devices. The TVT Registry helps professional soci-
eties be more involved in aspects of pre- and post-
market studies. Despite the challenges of launching
a national registry program with these goals, the
early years of the TVT Registry have included suc-
cessful national implementation of the program,
data reporting to stakeholders on the initial U.S.
TAVR experience, and approval for both a PAS and
an IDE study. It is hoped that the early TVT Reg-
istry experience will be helpful to other professional
societies and stakeholders in developing similar
programs.
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